Hepatitis C News and Research

Latest Hepatitis C News and Research

About 20% of surveyed sex workers who use drugs in Irish capital living with HIV, report finds

About one-fifth of commercial sex workers surveyed in Dublin, Ireland, are HIV-positive, while 78% of the surveyed group is living with hepatitis C, according to a report released Tuesday by the National Advisory Committee on Drugs, the Irish Times reports.

14 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

New insights into immune exhaustion

A main reason why viruses such as HIV or hepatitis C persist despite a vigorous initial immune response is exhaustion. The T cells, or white blood cells, fighting a chronic infection eventually wear out.

13 May 2009

HIV cases among young people in Iowa increasing

Health officials announced recently that the number of newly recorded HIV cases among Iowans ages 15 to 24 increased by 45% in 2008 to 16, despite the widespread availability of condoms and other prevention methods, the Iowa Press-Citizen reports.

12 May 2009

Pioneering technique for treatment of liver tumours

Leicester consultant surgeon who has developed a pioneering technique using microwaves to destroy liver tumours has treated more than 100 patients in the UK and other patients are now being treated internationally.

12 May 2009

New understanding on mechanisms of early stage liver reperfusion injury

Reperfusion of a previously ischemic tissue is associated with additional injury leading to structural and functional alterations in many organs including the liver.

7 May 2009

Scientists create human monoclonal antibody that neutralizes the Hepatitis C virus

Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).

5 May 2009

Women with a history of hypothyroidism at greater risk of developing liver cancer

Women with a history of hypothyroidism face a significantly higher risk of developing liver cancer, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience.

4 May 2009

Canadian Court to determine constitutionality of law preventing supervised drug-injection sites

The British Columbia Court of Appeals this week is hearing a case to decide whether certain sections of Canada's Controlled Drugs and Substances Act that prevent injection drug users from accessing services at the supervised drug-injection facility Insite in Vancouver, British Columbia, are constitutional, Toronto's Globe and Mail reports (Stueck, Globe and Mail, 4/28).

30 Apr 2009

Matrix protein key to fighting viruses

Researchers from Durham University's Centre for Bioactive Chemistry are developing methods that show how proteins interact with cell membranes when a virus strikes.

30 Apr 2009

Cancer rates among U.S. elderly, minorities set to explode

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45 percent, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from The University of Texas M. D. Anderson Cancer Center.

29 Apr 2009

Study predicts dramatic growth in cancer rates among US elderly, minorities

29 Apr 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Pharmasset, Inc. and Roche have announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic hepatitis C (HCV).

26 Apr 2009

Proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C

The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

23 Apr 2009

Diabetes, obesity and hypertension increase mortality in hepatitis C patients

The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

22 Apr 2009

Early treatment for hepatitis C offers a good chance of a cure

Australian researchers say as many as 70% of hepatitis C carriers can possibly be cured of the disease with early treatment - this is excellent news as hepatitis C, if left untreated can lead to serious liver disease.

22 Apr 2009

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

NanoBio has announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

20 Apr 2009

New updated clinical guidelines for HIV-associated opportunistic infections

The first complete update in five years of the U.S. guidelines for preventing and treating HIV-associated opportunistic infections has been released by the National Institutes of Health and the Centers for Disease Control and Prevention in cooperation with the HIV Medicine Association of the Infectious Diseases Society of America (IDSA).

16 Apr 2009

Do patients at risk for B-cell malignancy need antiviral treatment?

Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.

15 Apr 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

About 20% of surveyed sex workers who use drugs in Irish capital living with HIV, report finds

Cimzia approved in U.S. for rheumatoid arthritis

New insights into immune exhaustion

HIV cases among young people in Iowa increasing

Pioneering technique for treatment of liver tumours

New understanding on mechanisms of early stage liver reperfusion injury

Scientists create human monoclonal antibody that neutralizes the Hepatitis C virus

Women with a history of hypothyroidism at greater risk of developing liver cancer

Canadian Court to determine constitutionality of law preventing supervised drug-injection sites

Matrix protein key to fighting viruses

Cancer rates among U.S. elderly, minorities set to explode

Study predicts dramatic growth in cancer rates among US elderly, minorities

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C

Proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C

Diabetes, obesity and hypertension increase mortality in hepatitis C patients

Early treatment for hepatitis C offers a good chance of a cure

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

New updated clinical guidelines for HIV-associated opportunistic infections

Do patients at risk for B-cell malignancy need antiviral treatment?

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in